PG 2

Drug Profile

PG 2

Alternative Names: Injectable astragalus polysaccharide; PG2; PHN011; PHN012; PHN013; PHN014; PHN015; Polysaccharides of Astragalus membranaceus; XueBao

Latest Information Update: 21 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pharmagenesis
  • Developer Pharmagenesis; PhytoHealth
  • Class Phytotherapies; Polysaccharides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Immune thrombocytopenic purpura
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Fatigue; Leucopenia
  • Phase II Stroke
  • No development reported Idiopathic thrombocytopenic purpura

Most Recent Events

  • 21 Sep 2017 Discontinued - Phase-I/II for Leucopenia in Taiwan (IV)
  • 06 Sep 2017 PG 2 is still in phase II trials for Stroke in Taiwan (PhytoHealth Pipeline)
  • 15 Dec 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top